ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
A new targeted drug helps chronic leukemia patients who've failed multiple prior treatments achieve meaningful remission, offering hope in a difficult-to-treat group.
The ASC4OPT Phase 3b study of asciminib—a STAMP inhibitor targeting the ABL myristoyl pocket—demonstrated Major Molecular Response rates of 39.4% at 48 weeks and 43.6% at 96 weeks in 169 CML-CP patients who had failed two or more prior TKIs, with clinically meaningful dose escalation outcomes. Both 40mg BID and 80mg QD regimens showed similar efficacy with a consistent safety profile, supporting asciminib as a viable standard-of-care option in this difficult-to-treat population.
What the study was
- Study design
- Phase 3b non-comparative study (NCT04948333)
- Population
- CML-CP patients who failed ≥2 prior TKIs; n=169 in primary endpoint cohort (not in MMR at baseline); additional n=30 TKI-intolerant patients in MMR
- Sample size
- 199
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Leukemia
Why it surfaced
Phase 3b data for asciminib in heavily pretreated CML-CP (≥2 prior TKIs) with 43.6% MMR at 2 years and dose escalation path. Journal: Leukemia. Directly informs clinical practice for a subset of CML patients with limited options.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.